Close Menu

A team from Spain, China, Switzerland, and the US report on potential treatment targets and resistance mechanisms in KRAS-mutated forms of lung adenocarcinoma. Using genetically engineered mouse model experiments, pharmacological experiments, and other approaches, the team highlighted the potential for curbing lung adenocarcinoma growth by targeting RAF1 as well as cyclin-dependent kinases downstream of the MAP-kinase signaling pathway in advanced tumors driven by KRAS and p53.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.